Antimicrobial use in an Indonesian community cohort 0-18 months of age

PLoS One. 2019 Aug 5;14(8):e0219097. doi: 10.1371/journal.pone.0219097. eCollection 2019.

Abstract

Background: Antimicrobial resistance has become a global health emergency and is contributed to by inappropriate antibiotic use in community clinical settings. The aim of this study was to evaluate the antimicrobial use pattern in infants from birth until 18 months of age in Indonesia.

Methods: A post-hoc analysis was conducted in 1621 participants from the RV3BB Phase IIb trial conducted in Indonesia from January 2013 through July 2016. Any health events were documented in the trial as adverse events. Concomitant medication surveillance recorded all medications, including antibiotics during the 18 months of follow-up. Information included the frequency, duration of usage, formulation, classes, and their indications, including prophylactic antibiotic and perinatal use.

Results: Of 1621 participants, 551 (33.99%) received at least one antibiotic for treatment of infections during the 18 months observation period. Additionally, during the perinatal period, prophylactic antibiotics were used in 1244 (76.74%) participants and antibiotics consumed in 235 mothers of participants (14.50%). A total of 956 antibiotic consumptions were recorded for 18 months follow up, 67 (7.01%) as part of antimicrobial combinations. The average duration of antibiotic course was 4.92 days. Penicillin and sulfonamides were the most common antibiotic classes consumed (38.81% and 24.48%, respectively).

Conclusions: Despite the low community consumption rate, the overuse of antibiotic in URTIs and non-bloody diarrhea in our setting represents a major opportunity for antimicrobial stewardship, particularly in early life.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Antimicrobial Stewardship
  • Clinical Trials, Phase III as Topic
  • Cohort Studies
  • Drug Resistance, Bacterial
  • Female
  • Humans
  • Indonesia
  • Infant
  • Infant, Newborn
  • Male
  • Perinatal Care / statistics & numerical data
  • Residence Characteristics / statistics & numerical data*

Substances

  • Anti-Bacterial Agents

Grants and funding

The vaccine company PT Bio Farma provided support for this study in the form of a salary for the author NSB. The specific role of this author is articulated in the ‘author contributions’ section. Additionally, PT Biofarma was one of the funders of the RV3-BB Phase IIb trial. Another funding source of the RV3-BB Phase IIb trial was Murdoch Children’s Research Institute. The funders had roles in the study design, decision to publish, and preparation of the manuscript.